title: Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma.
abstract: OBJECTIVE
  We evaluated the long-term effects of treatment on the body mass index (BMI) of children with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma who received one of three CNS-directed therapies: intrathecal methotrexate with intravenous high-dose methotrexate (1 g/m2), intrathecal methotrexate with 18 Gy cranial radiation, or intrathecal methotrexate with 24 Gy cranial radiation.
  
  
  METHODS
  Between 1979 and 1984, 456 children with newly diagnosed ALL and lymphoma were enrolled onto a single protocol at St Jude Children's Research Hospital (Memphis, TN). The heights and weights of 422 of the children were measured at diagnosis, during treatment, at the end of therapy, and approximately every 6 to 12 months thereafter. Patients who had attained their adult height at the time of analysis (n = 248) were placed in weight categories based on their BMI, BMI percentile, or weight-for-length percentile depending on age.
  
  
  RESULTS
  The overall percentage of survivors who were overweight or obese approximated rates prevalent in the general population of the United States. Young age (< 6 years) and overweight/obesity at diagnosis were the best predictors of obesity at adult height. The rate of BMI increase did not differ significantly between children who received radiation and those who did not, nor between patients who received 18 or 24 Gy of cranial radiation.
  
  
  CONCLUSIONS
  BMI weight category at diagnosis, rather than type of CNS treatment received, predicted adult weight in long-term survivors of childhood hematologic malignancies.
authors.affiliation: Department of Hematology-Oncology, St Jude Children's Research Hospital and the University of Tennessee Health Science Center, Memphis, TN 38105-2794, USA. bassem.razzouk@stjude.org
authors.forename: Bassem I
authors.initials: BI
authors.lastname: Razzouk
authors.forename: Susan R
authors.initials: SR
authors.lastname: Rose
authors.forename: Suradej
authors.initials: S
authors.lastname: Hongeng
authors.forename: Dana
authors.initials: D
authors.lastname: Wallace
authors.forename: Matthew P
authors.initials: MP
authors.lastname: Smeltzer
authors.forename: Margie
authors.initials: M
authors.lastname: Zacher
authors.forename: Ching-Hon
authors.initials: CH
authors.lastname: Pui
authors.forename: Melissa M
authors.initials: MM
authors.lastname: Hudson
mesh_terms: D000293:Adolescent; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D015992:Body Mass Index; D002648:Child; D002675:Child, Preschool; D016371:Cranial Irradiation / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008137:Longitudinal Studies; D008297:Male; D008727:Methotrexate / Q000009:adverse effects*; D009765:Obesity / Q000209:etiology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000628:therapy*; D012189:Retrospective Studies
chemical_list: D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate